OB
O'Rourke Bridget
Director
BoardF
€264,834
▼ Sales (16 ops.)
Insider track record
Board DirectorAcross 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Browse the full record of transactions filed by O'Rourke Bridget, Director. Officer active across 1 company, notably Penumbra Inc. In total, 20 filings have been published. Split: 0 buy · 16 sells. Total volume traded: €265k. History available since 14 July 2021. The latest transaction was filed on 15 May 2025 (Cession). Regulator: SEC (Form 4). The full history is free.
Declarations20 total
100 shares@ US$286.159.7% of flowCommon StockSEC:0001704713-25-000003:0
50 shares@ US$271.214.5% of flowCommon StockSEC:0001321732-25-000078:0
50 shares@ US$285.485.2% of flowCommon StockSEC:0001321732-25-000045:0
744 shares0Common StockSEC:0001321732-25-000024:0
665 shares0Common StockSEC:0001321732-24-000012:0
150 shares@ US$226.4111.7% of flowCommon StockSEC:0001321732-23-000137:0
100 shares@ US$266.629.3% of flowCommon StockSEC:0001321732-23-000102:0
680 shares0Common StockSEC:0001321732-23-000030:0
88 shares@ US$191.206.5% of flowCommon StockSEC:0001321732-22-000085:0
88 shares@ US$137.124.4% of flowCommon StockSEC:0001321732-22-000069:0
88 shares@ US$135.004.4% of flowCommon StockSEC:0001321732-22-000067:0
710 shares0Common StockSEC:0001321732-22-000029:0
65 shares@ US$265.360.0001% mcap12.8% of flowCommon StockSEC:0001321732-21-000120:0
65 shares@ US$265.365.7% of flowCommon StockSEC:0001321732-21-000120
65 shares@ US$266.430.0001% mcap12.7% of flowCommon StockSEC:0001321732-21-000098:0
65 shares@ US$266.435.6% of flowCommon StockSEC:0001321732-21-000098
65 shares@ US$255.605.3% of flowCommon StockSEC:0001321732-21-000070
65 shares@ US$255.600.0001% mcap12.0% of flowCommon StockSEC:0001321732-21-000070:0
65 shares@ US$266.450.0001% mcap12.5% of flowCommon StockSEC:0001321732-21-000054:0
65 shares@ US$266.455.5% of flowCommon StockSEC:0001321732-21-000054
About O'Rourke Bridget
Bridget O'Rourke is a director at Penumbra Inc. She plays a key role in overseeing the company's activities and developing its strategy. Her expertise is essential for the development of innovative medical solutions.